Synteract Sponsoring and Presenting at Outsourcing in Clinical Trials Southeast Conference -Senior leadership in North Carolina office to co-present on how to identify viable trial sites for clinical research-
SAN DIEGO and RALEIGH-DURHAM, N.C., May 8, 2012 /PRNewswire/ -- Synteract, Inc., a full-service contract research organization (CRO), will be a corporate sponsor and have two senior level directors from its Research Triangle Park office speak at the inaugural Outsourcing in Clinical Trials Southeast conference to be held at the Durham Marriott Convention Center, May 15-16, 2012. Barbara Conley, associate director of clinical operations, and Matt Anders, associate director of project management, will co-present at 10:30 a.m. EDT, Wed., May 16th, on how to identify viable investigative sites that contribute to the success of a company's clinical study.
The conference series is nationally respected and attended by vendors and sponsors in the pharmaceutical and biotech industries. Conley and Ander's presentation will address one of the growing concerns within drug development; how to find and choose viable trial sites.
Topics will include:
- Identifying what makes a site feasible for your trial
- Establishing whether a site has ongoing studies competing for the same patient population
- Assessing whether the site meets the country's standard of care
- Forecasting whether the length of your trial is acceptable to investigational staff and patients
- Evaluating the availability of specialized equipment and expertise
- Analyzing the consistency of the investigator budget with the level of investigational site effort required
According to Synteract executives, with trial costs on the rise finding appropriate investigative sites is a key driver in efficient trial conduct. With site selection a critical component in the overall drug development process, it is important for biopharma companies of all sizes to work with a CRO that can facilitate choosing viable trial sites.
"After nearly two decades of operations, we're known for having a unique understanding of emerging pharma and biotech, particularly on the West Coast, where we are headquartered," stated Stewart Bieler, chief operating officer. "We continue to enhance the breadth and depth of our Raleigh-based service offering in response to increasing East Coast-based client demand. This allows us to continue to offer a level of individualized service from experienced clinical development professionals on each project."
Synteract will exhibit at booth #27. CEO Wendel Barr will be available to discuss the company's Shared Work-Shared Vision approach where every project and client receives collaborative, customized service that is tailored to their needs. To set up an appointment in advance, contact Michele Sacher, associate business development director, at 484.467.5937 or email@example.com
About Synteract (www.synteract.com)
Synteract is a full-service contract research organization with a successful 17-year track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. With its "Shared Work – Shared Vision" philosophy Synteract provides customized Phase I through IV services collaboratively and cost effectively to ensure on-time delivery of quality data so clients get to decision points faster. Headquartered in California, with offices in North Carolina and the Czech Republic, Synteract delivers trials internationally, offering expertise across multiple therapeutic areas including notable depth in oncology, CNS, cardiovascular, respiratory and ophthalmology.
Clearpoint Agency, for Synteract
SOURCE Synteract, Inc.